

MEETING AGENDA

EVENT:	Testing Surge Workgroup	Date / Time:	August 28, 2020 @ 1130
Author:	Lindsay Garfinkel, EY	Approved:	September 11, 2020

Enter information below: (text box will automatically expand, numbering is automatic)

Required Attendees (X=Present):

	NCDHHS	<i>Sec. Mandy Cohen</i>	X	NCDHHS	<i>Dr. Betsey Tilson</i>
X	NCDHHS	<i>Dr. Scott Shone</i>	X	NCDHHS	<i>Dr. Cardra Burns</i>
	NCDHHS	<i>Dr. Zack Moore</i>		NCDHHS	<i>Dr. Shannon Dowler</i>
	NCDHHS	<i>Jay Ludlam</i>	X	NCDHHS	<i>Azzie Conley</i>
X	NCDHHS	<i>Amanda Fuller-Moore</i>	X	LabCorp	<i>Traci Butler Clay Gibson</i>
X	Quest	<i>Natalie Jackson Betsey Swider</i>	X	Duke	<i>Dr. Michael Datto</i>
X	MAKO	<i>Josh Arant</i>		Atrium Health	<i>Dr. Gerald Capraro</i>
X	UNC Health	<i>Dr. Melissa Miller</i>	X	NC Medical Society	<i>Dr. Garrett Franklin</i>
	Old North State Medical Society	<i>Dr. Charlene Green</i>		NCCHCA	<i>Chris Shank</i>
	Community Rep	<i>Dr. Mark Massing</i>	X	Mecklenburg Cty	<i>Dr. Meg Sullivan</i>
X	NC Board of Pharmacy	<i>Jay Campbell</i>	X	NC Healthcare Association	<i>Dr. John Fallon or Dr. Mary Jo Cagle</i>
X	NCALHD	<i>Stacie Saunders and Lisa Macon Harrison</i>		NC Institute of Public Health	<i>Doug Urland</i>
X	Resolve to Save Lives	<i>Marina Smelyanskaya Lyz Ortiz</i>		UNC Gillings School of Global Public Health	<i>Dr. Kauline Cipriani</i>
	Manatt (in support of NC DHHS)	<i>Emily Carrier</i>		Guests:	<i>Natalie Ivanov, Rhonda Stephens, Aditi Mallick, Carlton Carroll, Chris Dobbins, Dana Webb-Randall, Jason S.</i>
X	Ernst & Young (in support of NC DHHS)	<i>Lindsay Garfinkel Marshall Turner, Brian Weeks</i>			

Agenda:

- I. **Welcome and Roll Call**—Dr. Burns (5 min)
- II. **Approval of August 21st Meeting Minutes**—Dr. Burns (5 min)
- III. **Opening Remarks**—Secretary Cohen, if available (5 min)
- IV. **New Business**
 - a. **Test Trends and Hot Topics**—Drs. Tilson, Moore, and Shone (15 min)

MEETING AGENDA

- Case Trends
- Revised CDC Testing Guidance
- b. **Strategies to Increase Testing Volume**—Dr. Tilson (10 min)
- c. **Respiratory Pathogen Surveillance and COVID Testing Follow-up Discussion**—Dr. Shone (15 min)
- d. **Scientific Council Progress update** (10 min)
 - Next Gen Sequencing—Dr. Datto
 - Saliva Testing —Dr. Fallon
- V. **Due Outs Assigned and Closing**—Drs. Burns, Tilson or Moore, if available (5 min)
 - No Meeting September 4th

Tasks / Due Outs: (List the recommended lead responsible for each task)

Due Date	Organization POC	Task
-	Zack Moore	Push messaging around NC's stance on testing guidance through provider channels
8/28	Scott Shone	Send the slide from the respiratory pathogen surveillance and COVID testing follow up discussion to Dr. Miller

Discussion by Major Topic: (Information not covered on slides or handouts)

- I. **Welcome and Roll Call**—Dr. Burns (5 min)
 - a. Dr. Cipriani is stepping down.
- II. **Approval of August 21st Meeting Minutes**—Dr. Burns (5 min)
 - a. There was a motion and a second; the minutes were approved.
- III. **Opening Remarks**—Secretary Cohen, if available (5 min)
- IV. **New Business**
 - a. **Test Trends and Hot Topics**—Drs. Tilson, Moore, and Shone (15 min)
 - i. Case Trends
 1. NC is overall trending in the right direction, but there has been an increase in cases in the 18-24 age group, likely associated with return to university.
 - ii. Consider creating a mass vaccination strategy workgroup soon.
 - iii. Revised CDC Testing Guidance
 1. Not changing NC's guidance.
 2. Everyone should follow control measures.
 - b. **Strategies to Increase Testing Volume**—Dr. Tilson (10 min)
 - i. Barriers:
 1. Testing fatigue.
 2. May not want to and/or be able to quarantine/isolate.

MEETING AGENDA

	<ul style="list-style-type: none"> 3. May be hesitant to get tested for fear of ICE being present at test sites. 4. May be waiting for a vaccine to come soon. 5. Age – different perspectives regarding the virus ii. Strategies: <ul style="list-style-type: none"> 1. Thinking through ways to increase access to testing in high priority populations and high-risk settings. 2. Enhance/rapidly deploy a mobile testing strategy. 3. Work with trusted partners. 4. Increase testing in communities that have college campuses. iii. Note: some communities are not seeing a downturn in testing, but rather an upturn. iv. College campuses: students who test positive are staying on campus for Q&I; known close contacts are directed to get a test before they leave campus; everyone is directed to quarantine/isolate for 14 days once they leave campus. c. Respiratory Pathogen Surveillance and COVID Testing Follow-up Discussion—Dr. Shone (15 min) <ul style="list-style-type: none"> i. Seeing what comes out at the national level. ii. Still working through this. iii. Discussed which tests to run and in which order based on symptomology and setting. iv. Discussed availability of platforms. v. A positive of a flu or COVID test does not rule out the other. d. Scientific Council Progress update (10 min) <ul style="list-style-type: none"> i. Next Gen Sequencing—Dr. Datto <ul style="list-style-type: none"> 1. Two have received EUA approval. 2. This could be beneficial in the clinical setting, but it is not cost effective. ii. Saliva Testing —Dr. Fallon <ul style="list-style-type: none"> 1. Saliva is significantly less sensitive than the NP test. V. Due Outs Assigned and Closing—Drs. Burns, Tilson or Moore, if available (5 min) <ul style="list-style-type: none"> a. No Meeting September 4th
<p>Next Meeting:</p>	<p>11 September 2020, 1130-1230 Microsoft Teams Link; Phone: 984-204-1487, Conference ID: 575 272 672#</p>